Brachytherapy · 2026
Randomized comparison of tandem-ring versus tandem-ovoid applicators in volume-based brachytherapy for cervical cancer: Dosimetric analysis and early clinical outcomes.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bonala Sreenivasa Rao, Raja Sorakayapet Arumugam, Subramanian Bala Venkat, Balaraju Siliveru, Sangeetha Mani
Аннотация
PURPOSE: This study compared dosimetry and early clinical outcomes of tandem-ring (T-R) and tandem-ovoid (T-O) applicators in cervical cancer patients treated with computed tomography (CT)-guided volume-based intracavitary brachytherapy (ICBT).
METHODS: Between April 2023 and June 2024, 36 eligible patients who completed pelvic external beam radiotherapy (EBRT) were randomized 1:1 to receive CT-guided volume-based ICBT with either T-O (n = 18; 72 applications) or T-R (n = 18; 72 applications). The EBRT consisted of 46 Gy in 23 fractions using 3-dimensional conformal radiotherapy (3DCRT). Brachytherapy was delivered as 28 Gy in 4 fractions (7Gy/fraction), twice weekly. The primary endpoint was rectal D2cc (EQD23), and the secondary endpoints included high-risk clinical target volume (HR-CTV) D90% and D98% (EQD210), bladder and sigmoid D2cc (EQD23), volumetric indices (V95%, V85%, V50%, and V20%), tumor response, and acute toxicity.
RESULTS: Mean rectal D2cc (EQD23) was reduced by 2.7 Gy (p = 0.04; 95% CI: 0.1-5.2) with T-R compared to T-O. Sigmoid D2cc decreased by 6.8 Gy (p = 0.005; 95% CI: 2.2-11.4), while bladder D2cc was comparable. HR-CTV D90%, D98%, and volumetric indices (V95%-V20%) were similar across groups. At a median follow-up of 7 months (range, 1-14), early clinical outcomes including complete response and acute GI/GU toxicities did not differ significantly.
CONCLUSION: This trial, the first randomized comparison of T-R and T-O applicators, demonstrated that T-R achieved significantly lower rectal and sigmoid doses while maintaining comparable bladder doses, HR-CTV coverage, and early outcomes. Longer follow-up is needed to confirm whether these dosimetric advantages translate to reduced late morbidity.
METHODS: Between April 2023 and June 2024, 36 eligible patients who completed pelvic external beam radiotherapy (EBRT) were randomized 1:1 to receive CT-guided volume-based ICBT with either T-O (n = 18; 72 applications) or T-R (n = 18; 72 applications). The EBRT consisted of 46 Gy in 23 fractions using 3-dimensional conformal radiotherapy (3DCRT). Brachytherapy was delivered as 28 Gy in 4 fractions (7Gy/fraction), twice weekly. The primary endpoint was rectal D2cc (EQD23), and the secondary endpoints included high-risk clinical target volume (HR-CTV) D90% and D98% (EQD210), bladder and sigmoid D2cc (EQD23), volumetric indices (V95%, V85%, V50%, and V20%), tumor response, and acute toxicity.
RESULTS: Mean rectal D2cc (EQD23) was reduced by 2.7 Gy (p = 0.04; 95% CI: 0.1-5.2) with T-R compared to T-O. Sigmoid D2cc decreased by 6.8 Gy (p = 0.005; 95% CI: 2.2-11.4), while bladder D2cc was comparable. HR-CTV D90%, D98%, and volumetric indices (V95%-V20%) were similar across groups. At a median follow-up of 7 months (range, 1-14), early clinical outcomes including complete response and acute GI/GU toxicities did not differ significantly.
CONCLUSION: This trial, the first randomized comparison of T-R and T-O applicators, demonstrated that T-R achieved significantly lower rectal and sigmoid doses while maintaining comparable bladder doses, HR-CTV coverage, and early outcomes. Longer follow-up is needed to confirm whether these dosimetric advantages translate to reduced late morbidity.